In this special TIBCS Channel interview, we are honored to welcome international breast cancer experts Dr. Dejan Juric and Dr. Kim Min-Hwan to discuss the evolving treatment landscape of HR+/HER2− breast cancer and what lies ahead.

The conversation explores key challenges in high-risk early breast cancer, including risk stratification, individualized treatment strategies, and the role of CDK4/6 inhibitors. The experts also discuss the rapidly evolving metastatic setting, with a focus on ADCs, patient selection, optimal timing, treatment sequencing, and emerging therapeutic strategies.

Reflecting the theme of TIBCS 2026, “Right Choice for Right Patient,” the discussion connects advances across early and metastatic breast cancer and considers how treatment decisions today may shape future therapeutic options. Looking ahead, Dr. Juric and Dr. Kim share their perspectives on the most important breakthroughs that could redefine clinical practice in HR+/HER2− breast cancer over the next 3–5 years.